Tests a risk-based screening method for prostate cancer across Europe
Studies a risk-based method to find prostate cancer early in men.
Plain-language title generated from the registry record
Registry title: Prostate Cancer Awareness and Initiative for Screening in the European Union
Key facts
- Where
- Wroclaw, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 69 years old?
Source: NCT06424275, who can take part
Where in Poland
- Lower Silesian Oncology, Pulmonology and Hematology CenterWroclaw, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European Association of Urology Research Foundation
- Trial code
- NCT06424275
- Record updated
- 15 August 2025
- Original description
PRAISE-U was initiated on the 1st of April 2023 and is set to last for three years. This collaborative effort involves 25 institutions across 12 countries, all driven by a shared objective: to rationalize prostate cancer screening in Europe and enhance patient outcomes. PRAISE-U advocates for EU member states to offer exceptional clinical standards, incorporating cutting-edge personalized approaches to enable timely detection of prostate cancer in individuals who can benefit from early treatment. To assess the functionality, feasibility, and long-term viability of a risk-based algorithm, the consortium will collaborate with pilot sites in Spain, Poland, Ireland, and Lithuania.Read full original descriptionShow less
Prostate Cancer Awareness and Initiative for Screening in the European Union
PRAISE-U was initiated on the 1st of April 2023 and is set to last for three years. This collaborative effort involves 25 institutions across 12 countries, all driven by a shared objective: to rationalize prostate cancer screening in Europe and enhance patient outcomes. PRAISE-U advocates for EU member states to offer exceptional clinical standards, incorporating cutting-edge personalized approaches to enable timely detection of prostate cancer in individuals who can benefit from early treatment. To assess the functionality, feasibility, and long-term viability of a risk-based algorithm, the consortium will collaborate with pilot sites in Spain, Poland, Ireland, and Lithuania.
Inclusion: Age 50-69 years old.
Exclusion: Previous diagnosis of prostate cancer; Unable to provide written informed consent; Had prostate biopsy or MRI within the past six months.